Scaling Up Development and Manufacturing at Speed: Meeting the Challenge of a Pandemic Response

Phacilitate
22 November 2021
SHARE NOW
Why collaboration is key to successfully scaling up at speed, in the context of developing, manufacturing and scaling up a vaccine for Covid-19.

9th December 2021
08:30 PST | 11:30 EST | 16:30 GMT | Alternative time zones 

When Covid-19 hit, scientists around the world worked together to address the huge challenge of producing an effective vaccine against the virus. It was this strong collaboration and expertise drawn from industry, academia, regulators and governments that made it possible to develop and manufacture a vaccine at speed. To date, more than 1.3 billion doses of the adenovirus-vectored vaccine ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) have been released for use.

During the pandemic, manufacturing has been the key factor limiting rollout of vaccination, requiring rapid development and large-scale implementation of novel manufacturing technologies.

This webinar will discuss the unique challenges when scaling up GMP manufacturing, exacerbated by the need to move at a very high speed whilst always ensuring that safety and regulatory requirements were satisfied.

Discover how Oxford Biomedica collaborated with The Jenner Institute to develop and manufacture the vaccine by ensuring the necessary skills, capacity, process and supply chains were all in place to help manufacture at the utmost speed and scale to meet the global demand for vaccine supplies.

Join James Miskin, Chief Technology Officer at Oxford Biomedica and Sandy Douglas, Research Group Leader at the University of Oxford as they discuss some of the key challenges associated with developing and commercialising an effective Covid-19 vaccine, and the application of these ideas to the advanced therapies commercialisation journey.

LEARNING OBJECTIVES
  • Develop a highly productive and cost-effective manufacturing process at speed
  • Ensure safety and regulatory requirements are satisfied
  • Harness a potentially unique strategy of distributed manufacturing of drug substance across a global network of sites
  • Collaboration between academia, contract manufacturers, and large pharma has helped enable and promote equitable vaccine access around the world 

The webinar includes an interactive Q&A.

This webinar will be hosted in partnership with Oxford Biomedica.

Phacilitate member? Register for the live event and on-demand access via the network.